Aragen Life Sciences ne Hyderabad mein apna naya 'Aragen OneHP' facility shuru kar diya hai. **15,000 square-foot** ka ye plant oncology (cancer) drugs banane ke kaam aayega.
Naya plant, nayi umeed!
Aragen Life Sciences ne apne Nacharam campus mein Aragen OneHP ka inauguration kiya hai. Ye facility khas taur par high-potency drugs banane ke liye bani hai, jismein cytotoxic payloads jaise sensitive compounds handle kiye jayenge. Iski capacity saal bhar mein 500 se 600 kg tak drug manufacturing ki hai. Ab clients ko alag-alag providers ke paas bhatakne ki zaroorat nahi padegi, kyunki yahan research se lekar manufacturing tak sab kuch ek hi chhat ke neeche hoga.
Paisa aur Growth ka connection
Ye expansion company ke us ₹1,000 Crore ke capital investment plan ka hissa hai jo March 2026 tak pura hua. Company CDMO sector mein apni pakad mazboot kar rahi hai.
IPO se pehle Financials dekho
August 2026 ki DRHP ke hisaab se, company ki performance kuch aisi rahi hai:
- Operating Revenue: ₹2,178 Crore
- Adjusted EBITDA: ₹593 Crore
- Net Profit: ₹283 Crore
Investors ke liye kuch Zaroori Baatein (Risks)
Sab kuch bullish nahi hai, doston. Kuch baatein note kar lo:
- Global Dependence: Company ka 90% se zyada revenue India ke bahar (US aur Europe) se aata hai. Agar wahan economic slowdown aaya, toh seedha asar padega.
- Competition: CDMO sector mein competition bahut tough hai. India, China, aur Eastern Europe ke players se constant ladai hai.
- Data Security: Client ki intellectual property (IP) protect karna inka main kaam hai. Zara si chook company ki reputation dubo sakti hai.
IPO aane wala hai, toh is facility ki progress aur naye contracts par nazar banaye rakhein!